SCHEMBL25327280

SCHEMBL25327280

CSc1ncc2c(C)cc(C3CCCC3)n2n1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1I2 O75469 1/20 0.33
KDM4B O94953 1/20 0.33
CHRM1 P11229 1/20 0.33
TBXA2R P21731 1/20 0.33
ADRA1A P35348 1/20 0.33
DOHH Q9BU89 1/20 0.33
KDM4E B2RXH2 3/20 0.33
HTT P42858 1/20 0.33
AURKA O14965 1/20 0.32
JAK1 P23458 1/20 0.32
TYK2 P29597 1/20 0.32
KDR P35968 1/20 0.32
FLT3 P36888 1/20 0.32
HPGD P15428 2/20 0.30
ALDH1A1 P00352 1/20 0.30
HSD17B10 Q99714 1/20 0.30
PDE2A O00408 1/20 0.30
MEN1 O00255 1/20 0.30
MAPT P10636 1/20 0.30
THRB P10828 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25328839 0.86 AURKA (0.30) AURKAJAK1TYK2KDRFLT3
SCHEMBL520589 0.75 AURKA (0.43) KDM4EHTTAURKAJAK1TYK2
SCHEMBL19222025 0.74 CKS1B (0.31) KDM4EHPGDALDH1A1HSD17B10
SCHEMBL26605786 0.68 FLT3 (0.33) KDM4EHTTAURKAJAK1TYK2
SCHEMBL17293604 0.66 KDM4E (0.41) KDM4EHTTMEN1KMT2A
SCHEMBL520341 0.66 KCNH2 (0.41)
SCHEMBL19348066 0.64 NFE2L2 (0.36) KDM4E
SCHEMBL31373962 0.63 CCNT1 (0.32)
SCHEMBL519840 0.63 KDM4E (0.31) KDM4E
SCHEMBL25326649 0.62 TLR8 (0.37) NR1I2KDM4BCHRM1TBXA2RADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250163063-A1 INHIBITORS OF CDK4/6 KINASE KHORA SPV 1, LLC 2025-05-22 US disclosed
EP-4469062-A1 INHIBITORS OF CDK4/6 KINASE Kinnate Biopharma Inc. (US) 2024-12-04 EP disclosed
CN-119013030-A Inhibitors of CDK4/6 kinase 金耐特生物制药公司 2024-11-22 CN disclosed
WO-2023147372-A1 INHIBITORS OF CDK4/6 KINASE KINNATE BIOPHARMA INC. (US) 2023-08-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250163063-A1 INHIBITORS OF CDK4/6 KINASE CDK4, CDK6, CDK2 NR1I2 2916/4885KDM4B 1108/4885CHRM1 4885/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.